CA2942713A1 - Compositions and methods for treatment of diabetic macular edema - Google Patents

Compositions and methods for treatment of diabetic macular edema Download PDF

Info

Publication number
CA2942713A1
CA2942713A1 CA2942713A CA2942713A CA2942713A1 CA 2942713 A1 CA2942713 A1 CA 2942713A1 CA 2942713 A CA2942713 A CA 2942713A CA 2942713 A CA2942713 A CA 2942713A CA 2942713 A1 CA2942713 A1 CA 2942713A1
Authority
CA
Canada
Prior art keywords
antibody
pkal
active
human
antibodies
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA2942713A
Other languages
English (en)
French (fr)
Inventor
Gregory P. Conley
Daniel J. Sexton
Andrew Nixon
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Takeda Pharmaceutical Co Ltd
Original Assignee
Dyax Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dyax Corp filed Critical Dyax Corp
Publication of CA2942713A1 publication Critical patent/CA2942713A1/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A61K9/0051—Ocular inserts, ocular implants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Dermatology (AREA)
CA2942713A 2014-03-27 2015-03-26 Compositions and methods for treatment of diabetic macular edema Pending CA2942713A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201461971170P 2014-03-27 2014-03-27
US61/971,170 2014-03-27
PCT/US2015/022715 WO2015148790A1 (en) 2014-03-27 2015-03-26 Compositions and methods for treatment of diabetic macular edema

Publications (1)

Publication Number Publication Date
CA2942713A1 true CA2942713A1 (en) 2015-10-01

Family

ID=54189389

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2942713A Pending CA2942713A1 (en) 2014-03-27 2015-03-26 Compositions and methods for treatment of diabetic macular edema

Country Status (9)

Country Link
US (3) US10428158B2 (cg-RX-API-DMAC7.html)
EP (1) EP3122782A4 (cg-RX-API-DMAC7.html)
JP (4) JP6719384B2 (cg-RX-API-DMAC7.html)
KR (2) KR102555955B1 (cg-RX-API-DMAC7.html)
CN (1) CN106459210A (cg-RX-API-DMAC7.html)
AU (3) AU2015235967B2 (cg-RX-API-DMAC7.html)
CA (1) CA2942713A1 (cg-RX-API-DMAC7.html)
IL (2) IL295414B1 (cg-RX-API-DMAC7.html)
WO (1) WO2015148790A1 (cg-RX-API-DMAC7.html)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE60333758D1 (de) 2002-06-07 2010-09-23 Dyax Corp Prevention und Verringerung von Ischemia
SI3459564T1 (sl) 2010-01-06 2022-06-30 Takeda Pharmaceutical Company Limited Proteini, ki vežejo plazemski kalikrein
JO3417B1 (ar) 2010-01-08 2019-10-20 Regeneron Pharma الصيغ المستقرة التي تحتوي على الأجسام المضادة لمضاد مستقبل( interleukin-6 (il-6r
JP2014506257A (ja) * 2011-01-06 2014-03-13 ダイアックス コーポレーション 血漿カリクレイン結合タンパク質
CN111704672B (zh) 2013-03-15 2024-06-04 武田药品工业株式会社 抗血浆激肽释放酶抗体
EA038532B1 (ru) 2014-01-21 2021-09-10 Такеда Фармасьютикал Компани Лимитед Способ лечения наследственного ангионевротического отека (hae)
IL295414B1 (en) 2014-03-27 2025-10-01 Takeda Pharmaceuticals Co Compositions and methods for treating macular edema due to diabetes
CA3003874A1 (en) 2015-11-03 2017-05-11 Sanofi Biotechnology Compositions comprising il6r antibodies for the treatment of uveitis and macular edema and methods of using same
SG10202004083UA (en) * 2015-11-03 2020-05-28 Sanofi Biotechnology Compositions comprising il6r antibodies for the treatment of uveitis and macular edema and methods of using same
US11286307B2 (en) 2015-12-11 2022-03-29 Takeda Pharmaceutical Company Limited Plasma kallikrein inhibitors and uses thereof for treating hereditary angioedema attack
US10894833B2 (en) * 2017-07-20 2021-01-19 H. Lundbeck A/S Agents, uses and methods for treatment
MX2021002349A (es) * 2018-08-30 2021-05-31 Takeda Pharmaceuticals Co Inhibidores de calicreína en plasmá y usos de los mismos para tratar ataque de angioedema hereditario.
KR20210122810A (ko) 2019-01-31 2021-10-12 사노피 바이오테크놀로지 청소년 특발성 관절염을 치료하기 위한 항 il-6 수용체 항체
AU2020273154A1 (en) * 2019-04-08 2021-12-02 Biocryst Pharmaceuticals, Inc. Plasma kallikrein inhibitors and methods of use thereof in ocular disorders
EP3959240A1 (en) 2019-04-24 2022-03-02 Sanofi Biotechnology Methods of diagnosis and treatment of rheumatoid arthritis
AU2020288561A1 (en) 2019-06-04 2021-12-23 Regeneron Pharmaceuticals, Inc. Compositions and methods for treating pain in subjects with rheumatoid arthritis
EP3983449A1 (en) * 2019-06-11 2022-04-20 Shire Human Genetic Therapies, Inc. Adeno associated viral vector delivery of antibodies for the treatment of disease mediated dysregulated plasma kallikrein
US10975169B1 (en) * 2019-09-27 2021-04-13 Memorial Sloan Kettering Cancer Center Methods for treating diabetic retinopathy using anti-ceramide monoclonal antibody 2A2
US20240218079A1 (en) * 2021-01-28 2024-07-04 Astria Therapeutics, Inc. Plasma kallikrein antibodies and uses thereof

Family Cites Families (244)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR6915369D0 (pt) 1969-02-27 1973-03-13 Bayer Ag Emprego de inibidores biologicos de proteases para conservacao de orgaos tecidos e alimentos
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
US3691016A (en) 1970-04-17 1972-09-12 Monsanto Co Process for the preparation of insoluble enzymes
CA1023287A (en) 1972-12-08 1977-12-27 Boehringer Mannheim G.M.B.H. Process for the preparation of carrier-bound proteins
US4179337A (en) 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
DE2619246A1 (de) 1976-04-30 1977-11-10 Bayer Ag Desamino-derivate des kallikrein- trypsin-inhibitors, verfahren zu ihrer herstellung sowie ihre verwendung als arzneimittel
US4195128A (en) 1976-05-03 1980-03-25 Bayer Aktiengesellschaft Polymeric carrier bound ligands
DE2654124A1 (de) 1976-11-29 1978-06-01 Bayer Ag Derivate des trypsin-kallikrein-inhibitors aus rinderorganen (bpti) mit proteasenhemmwirkung und antiphlogistischer wirkung, ihre herstellung und ihre verwendung als arzneimittel
US4330440A (en) 1977-02-08 1982-05-18 Development Finance Corporation Of New Zealand Activated matrix and method of activation
CA1093991A (en) 1977-02-17 1981-01-20 Hideo Hirohara Enzyme immobilization with pullulan gel
US4229537A (en) 1978-02-09 1980-10-21 New York University Preparation of trichloro-s-triazine activated supports for coupling ligands
AT359653B (de) 1979-02-15 1980-11-25 Immuno Ag Verfahren zur herstellung eines gewebekleb- stoffes
US5179017A (en) 1980-02-25 1993-01-12 The Trustees Of Columbia University In The City Of New York Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4634665A (en) 1980-02-25 1987-01-06 The Trustees Of Columbia University In The City Of New York Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4399216A (en) 1980-02-25 1983-08-16 The Trustees Of Columbia University Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4447233A (en) 1981-04-10 1984-05-08 Parker-Hannifin Corporation Medication infusion pump
US4485045A (en) 1981-07-06 1984-11-27 Research Corporation Synthetic phosphatidyl cholines useful in forming liposomes
US4447224A (en) 1982-09-20 1984-05-08 Infusaid Corporation Variable flow implantable infusion apparatus
US4544545A (en) 1983-06-20 1985-10-01 Trustees University Of Massachusetts Liposomes containing modified cholesterol for organ targeting
AU560584B2 (en) 1983-07-28 1987-04-09 Bayer Aktiengesellschaft Homologues of aprotinin
US4657893A (en) 1984-05-09 1987-04-14 Syntex (U.S.A.) Inc. 4H-3,1-benzoxazin-4-ones and related compounds and use as enzyme inhibitors
US4845242A (en) 1987-04-28 1989-07-04 Georgia Tech Research Corporation Isocoumarins with basic substituents as serine proteases inhibitors, anticoagulants and anti-inflammatory agents
US4609725A (en) 1984-10-09 1986-09-02 Merck & Co., Inc. Cardiac atrial peptides
US4931385A (en) 1985-06-24 1990-06-05 Hygeia Sciences, Incorporated Enzyme immunoassays and immunologic reagents
US5444156A (en) 1985-07-12 1995-08-22 Temple University-Of The Commonwealth System Of Higher Education Monoclonal antibodies to human plasma prekallikrein
US4777127A (en) 1985-09-30 1988-10-11 Labsystems Oy Human retrovirus-related products and methods of diagnosing and treating conditions associated with said retrovirus
GB8601597D0 (en) 1986-01-23 1986-02-26 Wilson R H Nucleotide sequences
EP0296171A4 (en) 1986-03-03 1989-11-07 Brigham & Womens Hospital ASSESSMENT PROCEDURE FOR NEPHROTOXICITY.
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
US4704692A (en) 1986-09-02 1987-11-03 Ladner Robert C Computer based system and method for determining and displaying possible chemical structures for converting double- or multiple-chain polypeptides to single-chain polypeptides
US5260203A (en) 1986-09-02 1993-11-09 Enzon, Inc. Single polypeptide chain binding molecules
US4881175A (en) 1986-09-02 1989-11-14 Genex Corporation Computer based system and method for determining and displaying possible chemical structures for converting double- or multiple-chain polypeptides to single-chain polypeptides
US5187153A (en) 1986-11-17 1993-02-16 Scios Nova Inc. Methods of treatment using Alzheimer's amyloid polypeptide derivatives
US5217951A (en) 1986-12-24 1993-06-08 John Lezdey Treatment of inflammation
IL85035A0 (en) 1987-01-08 1988-06-30 Int Genetic Eng Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
GB8702816D0 (en) 1987-02-07 1987-03-11 Al Sumidaie A M K Obtaining retrovirus-containing fraction
US5219740A (en) 1987-02-13 1993-06-15 Fred Hutchinson Cancer Research Center Retroviral gene transfer into diploid fibroblasts for gene therapy
IL87172A (en) 1987-07-23 1994-12-29 Univ Washington Method of isolating highly purified tissue factor inhibitor
US4966852A (en) 1987-07-23 1990-10-30 Monsanto Company DNA clone of human tissue factor inhibitor
US5106833A (en) 1987-07-23 1992-04-21 Washington University Coagulation inhibitors
GB2208511A (en) 1987-08-07 1989-04-05 Bayer Ag Variants of bovine pancreatic trypsin inhibitor produced by recombinant dna technology
DK225488D0 (da) 1988-04-26 1988-04-26 Novo Industri As Polypeptid
US5422120A (en) 1988-05-30 1995-06-06 Depotech Corporation Heterovesicular liposomes
AP129A (en) 1988-06-03 1991-04-17 Smithkline Biologicals S A Expression of retrovirus gag protein eukaryotic cells
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
US5663143A (en) 1988-09-02 1997-09-02 Dyax Corp. Engineered human-derived kunitz domains that inhibit human neutrophil elastase
US7078383B2 (en) 1988-09-02 2006-07-18 Dyax Corp. ITI-D1 Kunitz domain mutants as HNE inhibitors
US5045452A (en) 1988-09-02 1991-09-03 Brigham And Women's Hospital Method for evaluating nephrotoxicity
US5372933A (en) 1988-10-03 1994-12-13 The Scripps Research Institute Polypeptides that mimic receptor-induced binding sites, and methods of using same
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
WO1990007936A1 (en) 1989-01-23 1990-07-26 Chiron Corporation Recombinant therapies for infection and hyperproliferative disorders
US5703055A (en) 1989-03-21 1997-12-30 Wisconsin Alumni Research Foundation Generation of antibodies through lipid mediated DNA delivery
ES2200016T3 (es) 1989-03-21 2004-03-01 Vical Incorporated Expresion de secuencias polinucleotidicas exogenas en un vertebrado.
EP0401508B1 (de) 1989-05-13 1994-11-23 Bayer Ag Proteinaseninhibitoren, Verfahren zu ihrer Herstellung sowie diese enthaltende Arzneimittel
US5378614A (en) 1989-08-18 1995-01-03 Novo Nordisk A/S Vector and method for making tissue factor pathway inhibitor (TFPI) analogues in yeast
WO1991002805A2 (en) 1989-08-18 1991-03-07 Viagene, Inc. Recombinant retroviruses delivering vector constructs to target cells
DK408089D0 (da) 1989-08-18 1989-08-18 Novo Nordisk As Proteiner
US5585362A (en) 1989-08-22 1996-12-17 The Regents Of The University Of Michigan Adenovirus vectors for gene therapy
US5013556A (en) 1989-10-20 1991-05-07 Liposome Technology, Inc. Liposomes with enhanced circulation time
US5278285A (en) 1990-02-01 1994-01-11 Bayer Aktiengesellschaft Variant of Kunitz-type inhibitor derived from the α3-chain of human type VI collagen produced by recombinant DNA technology
NZ237464A (en) 1990-03-21 1995-02-24 Depotech Corp Liposomes with at least two separate chambers encapsulating two separate biologically active substances
US5427908A (en) 1990-05-01 1995-06-27 Affymax Technologies N.V. Recombinant library screening methods
US5583107A (en) 1990-09-04 1996-12-10 Cor Therapeutics, Inc. Agents affecting thrombosis and hemostasis
US5278144A (en) 1990-09-04 1994-01-11 Cor Therapeutics, Inc. Antithrombosis agents
US5409895A (en) 1990-11-13 1995-04-25 Mochida Pharmaceutical Co., Ltd. Protease inhibitory polypeptides derived from urinary trypsin inhibitor and compositions thereof
US20030223977A1 (en) 1991-03-01 2003-12-04 Ley Arthur Charles Kunitz domain mutants as cathepsin G inhibitors
US5166133A (en) 1991-04-17 1992-11-24 Cetus Corporation Method for inhibing adhesion of white blood cells to endothelial cells
CA2103059C (en) 1991-06-14 2005-03-22 Paul J. Carter Method for making humanized antibodies
ES2197145T3 (es) 1991-08-20 2004-01-01 The Government Of The Usa As Represented By The Secretary Of The Deptm. Of Health And Human Services Transferencia de genes mediada por adenovirus al gastrointestinal.
CA2116774C (en) 1991-09-19 2003-11-11 Paul J. Carter Expression in e. coli antibody fragments having at least a cysteine present as a free thiol. use for the production of bifunctional f(ab') 2 antibodies
US5565332A (en) 1991-09-23 1996-10-15 Medical Research Council Production of chimeric antibodies - a combinatorial approach
WO1993010218A1 (en) 1991-11-14 1993-05-27 The United States Government As Represented By The Secretary Of The Department Of Health And Human Services Vectors including foreign genes and negative selective markers
GB9125623D0 (en) 1991-12-02 1992-01-29 Dynal As Cell modification
IL104325A (en) 1992-01-07 2000-10-31 Novo Nordisk As Variants of human kunitz-type protease inhibitor domain II of tissue factor pathway inhibitor (TFPI) pharmaceutical compositions containing them a DNA construct encoding them their expression vectors a cell containing said DNA constructs and methods for the production of all the above
IL104314A0 (en) 1992-01-07 1993-05-13 Novo Nordisk As Human kunitz-type protease inhibitor and variants thereof,their production and pharmaceutical compositions containing them
IL104327A0 (en) 1992-01-07 1993-05-13 Novo Nordisk As Variant of human kunitz-type protease inhibitor
US5212091A (en) 1992-03-02 1993-05-18 Monsanto Company Method of producing tissue factor pathway inhibitor
FR2688514A1 (fr) 1992-03-16 1993-09-17 Centre Nat Rech Scient Adenovirus recombinants defectifs exprimant des cytokines et medicaments antitumoraux les contenant.
US5733743A (en) 1992-03-24 1998-03-31 Cambridge Antibody Technology Limited Methods for producing members of specific binding pairs
US6063764A (en) 1992-06-01 2000-05-16 Washington University & Chiron Corp. Method for using lipoprotein associated coagulation inhibitor to treat sepsis
WO1993025234A1 (en) 1992-06-08 1993-12-23 The Regents Of The University Of California Methods and compositions for targeting specific tissue
JPH09507741A (ja) 1992-06-10 1997-08-12 アメリカ合衆国 ヒト血清による不活性化に耐性のあるベクター粒子
US5747449A (en) 1992-07-13 1998-05-05 Corvas International, Inc. Bovine pancreatic trypsin inhibitor derived inhibitors of factor XA
GB2269175A (en) 1992-07-31 1994-02-02 Imperial College Retroviral vectors
IL107831A0 (en) 1992-12-02 1994-05-30 Zymogenetics Inc Novel human amyloid protein precursor homolog and kunitz-type inhibitor
US5436153A (en) 1992-12-02 1995-07-25 Sprecher; Cindy A. Human amyloid protein precursor homolog and Kunitz-type inhibitor
JPH08503855A (ja) 1992-12-03 1996-04-30 ジェンザイム・コーポレイション 嚢胞性線維症に対する遺伝子治療
US5981568A (en) 1993-01-28 1999-11-09 Neorx Corporation Therapeutic inhibitor of vascular smooth muscle cells
US5426224A (en) 1993-03-18 1995-06-20 The University Of North Carolina At Chapel Hill Mammalian DNA topoisomerase II inhibitor and method
EP0695169B1 (en) 1993-04-22 2002-11-20 SkyePharma Inc. Multivesicular cyclodextrin liposomes encapsulating pharmacologic compounds and methods for their use
AU687829B2 (en) 1993-06-24 1998-03-05 Advec, Inc. Adenovirus vectors for gene therapy
EP0719334A1 (en) 1993-09-14 1996-07-03 Genentech, Inc. Pharmaceutical compositions containing ecotin and homologs thereof
DE69433461T2 (de) 1993-09-15 2004-11-18 Chiron Corp. (N.D.Ges.D. Staates Delaware), Emeryville Rekombinanter Alphavirus Vektor
US6015686A (en) 1993-09-15 2000-01-18 Chiron Viagene, Inc. Eukaryotic layered vector initiation systems
HU223733B1 (hu) 1993-10-25 2004-12-28 Canji, Inc. Rekombináns adenovírus vektor és eljárás alkalmazására
US5455338A (en) 1993-11-05 1995-10-03 Zymogenetics, Inc. DNA encoding novel human kunitz-type inhibitors and methods relating thereto
US5951974A (en) 1993-11-10 1999-09-14 Enzon, Inc. Interferon polymer conjugates
US5446090A (en) 1993-11-12 1995-08-29 Shearwater Polymers, Inc. Isolatable, water soluble, and hydrolytically stable active sulfones of poly(ethylene glycol) and related polymers for modification of surfaces and molecules
KR100241300B1 (ko) 1993-11-16 2000-03-02 Sheldon A. Schaffer 활성물질의 조절된 방출성을 갖는 소포
US5759548A (en) 1993-11-30 1998-06-02 Lxr Biotechnology Inc. Compositions which inhibit apoptosis, methods of purifying the compositions and uses thereof
US5827690A (en) 1993-12-20 1998-10-27 Genzyme Transgenics Corporatiion Transgenic production of antibodies in milk
US6057287A (en) 1994-01-11 2000-05-02 Dyax Corp. Kallikrein-binding "Kunitz domain" proteins and analogues thereof
ATE529444T1 (de) 1994-01-11 2011-11-15 Dyax Corp Inhibitoren des humanplasmins, die sich von den kunitz domänen ableiten
ES2227545T3 (es) 1994-01-11 2005-04-01 Dyax Corporation Proteinas y sus analogos del "dominio de kunitz" inhibidores de calicreina.
US5795954A (en) 1994-03-04 1998-08-18 Genentech, Inc. Factor VIIa inhibitors from Kunitz domain proteins
CA2158977A1 (en) 1994-05-09 1995-11-10 James G. Respess Retroviral vectors having a reduced recombination rate
JP3721538B2 (ja) 1994-06-02 2005-11-30 メレル ファーマスーティカルズ インコーポレイテッド エラスターゼのパーフルオロアルキルケトン阻害剤およびそれらを製造する方法
EP0774001B1 (en) 1994-08-05 2002-10-16 Chiron Corporation Production of tissue factor pathway inhibitor
US5589359A (en) 1994-08-05 1996-12-31 Chiron Corporation Chimeric proteins
US5648331A (en) 1994-08-26 1997-07-15 G.D. Searle & Co. Method of inhibiting tissue ischemia and reperfusion injury
NZ296648A (en) 1994-10-18 2001-05-25 Corvas Int Inc Nematode-extracted serine protease inhibitors and anticoagulant proteins
US6159938A (en) 1994-11-21 2000-12-12 Cortech, Inc. Serine protease inhibitors comprising α-keto heterocycles
WO1996017072A2 (en) 1994-11-30 1996-06-06 Chiron Viagene, Inc. Recombinant alphavirus vectors
JPH10510540A (ja) 1994-12-12 1998-10-13 オメロス メディカル システムズ，インコーポレーテッド 灌注用溶液並びに疼痛、炎症及びけいれんの抑制法
ES2377126T3 (es) 1994-12-12 2012-03-22 Omeros Corporation Solución de irrigación y utilización de la misma para la inhibición perioperatoria del dolor, la inflamación y/o los espasmos en una estructura vascular
US5914316A (en) 1994-12-16 1999-06-22 Washington University Method of inhibiting intimal hyperplasia
US5932462A (en) 1995-01-10 1999-08-03 Shearwater Polymers, Inc. Multiarmed, monofunctional, polymer for coupling to molecules and surfaces
ES2208737T3 (es) 1995-03-10 2004-06-16 Berlex Laboratories, Inc. Derivados de benzamidina, su preparacion y su utilizacion como anticoagulantes.
US5695760A (en) 1995-04-24 1997-12-09 Boehringer Inglehiem Pharmaceuticals, Inc. Modified anti-ICAM-1 antibodies and their use in the treatment of inflammation
US5804376A (en) 1995-05-02 1998-09-08 Incyte Pharmaceuticals, Inc. Pancreas-derived serpin
ZA963619B (en) 1995-05-08 1996-11-22 Scios Inc Protease inhibitor peptides
US5786328A (en) 1995-06-05 1998-07-28 Genentech, Inc. Use of kunitz type plasma kallikrein inhibitors
US5780265A (en) 1995-06-05 1998-07-14 Genentech, Inc. Kunitz type plasma kallikrein inhibitors
US6242414B1 (en) 1995-06-07 2001-06-05 Chiron Corporation Regulation of cytokine synthesis and release
US6265150B1 (en) 1995-06-07 2001-07-24 Becton Dickinson & Company Phage antibodies
US6126933A (en) 1995-06-27 2000-10-03 Genetics Institute Methods of treating inflammatory bowel diseases by administering IL-11
US5672662A (en) 1995-07-07 1997-09-30 Shearwater Polymers, Inc. Poly(ethylene glycol) and related polymers monosubstituted with propionic or butanoic acids and functional derivatives thereof for biotechnical applications
AU7071896A (en) 1995-09-14 1997-04-01 Lxr Biotechnology Inc. Compositions with anti-apoptotic activity, containing a mixture of phospholipids
KR19990063648A (ko) 1995-09-21 1999-07-26 프레드한 아룬디프 에스 글루타민산 데카복실라제에 대한 항체와 폴리(에틸렌 글리콜)공액물을 섬세포에 제공하는 방법
US5824870A (en) 1995-11-06 1998-10-20 Baszczynski; Chris Commercial production of aprotinin in plants
US5736364A (en) 1995-12-04 1998-04-07 Genentech, Inc. Factor viia inhibitors
TR199801794T2 (xx) 1996-03-11 2000-07-21 Bayer Corporation �nsan bikunini.
AU2998597A (en) 1996-05-06 1997-11-26 Chiron Corporation Crossless retroviral vectors
US6013763A (en) 1996-06-04 2000-01-11 Genentech, Inc. Peptide variants of protein A
US5869637A (en) 1996-07-22 1999-02-09 Incyte Pharmaceuticals, Inc. Human Kallikrein
DE19632772A1 (de) 1996-08-14 1998-02-19 Basf Ag Neue Benzamidine
US6214966B1 (en) 1996-09-26 2001-04-10 Shearwater Corporation Soluble, degradable poly(ethylene glycol) derivatives for controllable release of bound molecules into solution
US6255455B1 (en) 1996-10-11 2001-07-03 The Trustees Of The University Of Pennsylvania Rh(D)-binding proteins and magnetically activated cell sorting method for production thereof
US6258351B1 (en) 1996-11-06 2001-07-10 Shearwater Corporation Delivery of poly(ethylene glycol)-modified molecules from degradable hydrogels
US5840871A (en) 1997-01-29 1998-11-24 Incyte Pharmaceuticals, Inc. Prostate-associated kallikrein
WO1998033920A2 (en) 1997-01-31 1998-08-06 Human Genome Sciences, Inc. Tissue factor pathway inhibitor-3
US5962300A (en) 1997-03-26 1999-10-05 Incyte Pharmaceuticals, Inc. Human kallikrein
US5990237A (en) 1997-05-21 1999-11-23 Shearwater Polymers, Inc. Poly(ethylene glycol) aldehyde hydrates and related polymers and applications in modifying amines
JP2003525845A (ja) 1997-10-28 2003-09-02 ヴィヴァス・インコーポレイテッド 勃起機能不全の処置のためのホスホジエステラーゼインヒビターの局所投与
EP1053019B1 (en) 1998-01-07 2003-12-03 Debio Recherche Pharmaceutique S.A. Degradable heterobifunctional poly(ethylene glycol) acrylates and gels and conjugates derived therefrom
EP1061954B1 (en) 1998-03-12 2004-06-09 Nektar Therapeutics Al, Corporation Poly(ethylene glycol) derivatives with proximal reactive groups
AU2855499A (en) 1998-03-24 1999-10-18 Nof Corporation Oxirane derivatives and process for producing the same
US6017723A (en) 1998-03-27 2000-01-25 Long Island Jewish Medical Center Method for isolating inhibitors of protease activity
US6001596A (en) 1998-05-07 1999-12-14 Incyte Pharmaceuticals, Inc. Growth-associated protease inhibitor heavy chain precursor
GB9809951D0 (en) 1998-05-08 1998-07-08 Univ Cambridge Tech Binding molecules
US6087473A (en) 1999-05-26 2000-07-11 Zymogenetics, Inc. Kunitz domain polypeptide and materials and methods for making it
US6783965B1 (en) 2000-02-10 2004-08-31 Mountain View Pharmaceuticals, Inc. Aggregate-free urate oxidase for preparation of non-immunogenic polymer conjugates
EP2158923B1 (en) 1998-08-06 2013-02-27 Mountain View Pharmaceuticals, Inc. Peg-urate oxidase conjugates and use thereof
US7067144B2 (en) 1998-10-20 2006-06-27 Omeros Corporation Compositions and methods for systemic inhibition of cartilage degradation
US6565874B1 (en) 1998-10-28 2003-05-20 Atrix Laboratories Polymeric delivery formulations of leuprolide with improved efficacy
WO2000032772A2 (en) 1998-11-30 2000-06-08 Eli Lilly And Company Erythropoietic compounds
WO2000053211A2 (en) 1999-03-09 2000-09-14 University Of Southern California Method of promoting myocyte proliferation and myocardial tissue repair
US20030012969A1 (en) 1999-04-06 2003-01-16 Clark Bert Thomas Soluble membrane strengthened paper products
US6174859B1 (en) 1999-04-06 2001-01-16 J & D Sciences, Inc. Method of treatment
US6180607B1 (en) 1999-08-05 2001-01-30 Christopher Davies Protein having proteinase inhibitor activity
HRP20020387A2 (en) 1999-11-12 2005-10-31 Maxygen Holdings Ltd. Interferon gamma conjugates
US6348558B1 (en) 1999-12-10 2002-02-19 Shearwater Corporation Hydrolytically degradable polymers and hydrogels made therefrom
AU781729B2 (en) 1999-12-22 2005-06-09 Nektar Therapeutics Method for the preparation of 1-benzotriazolyl carbonate esters of poly(ethylene glycol)
US6544760B2 (en) 1999-12-22 2003-04-08 Zymogenetics, Inc. Kunitz domain polypeptide Zkun11
US6413507B1 (en) 1999-12-23 2002-07-02 Shearwater Corporation Hydrolytically degradable carbamate derivatives of poly (ethylene glycol)
US20020102703A1 (en) 1999-12-29 2002-08-01 Sheppard Paul O. Kunitz domain polypeptide zkun10
GB9930882D0 (en) 1999-12-30 2000-02-23 Nps Allelix Corp GLP-2 formulations
CA2419979A1 (en) 2000-09-08 2002-03-14 Schering Corporation Mammalian genes; related reagents and methods
PT1223972E (pt) 2000-10-31 2003-11-28 Debiopharm Sa Suspensao de uma proteina de epi-hne processo para a sua preparacao aerossol de po anidro derivado dela composicoes farmaceuticas contendo a referida suspensao ou aerossol e as suas utilizacoes
US20030113726A1 (en) 2000-12-04 2003-06-19 Zenta Tsuchihashi Human single nucleotide polymorphisms
DE10060653A1 (de) 2000-12-06 2002-06-20 Epcos Ag Elektrischer Doppelschicht-Kondensator
TW593427B (en) 2000-12-18 2004-06-21 Nektar Therapeutics Al Corp Synthesis of high molecular weight non-peptidic polymer derivatives
US20040152633A1 (en) 2001-05-31 2004-08-05 Jorgensen Marianne Ulrich Kunitz-type sequences and polypeptides
AU2002358921A1 (en) 2001-07-10 2003-04-28 Omnio Ab Novel drug targets for arthritis
CA2466034C (en) 2001-11-08 2012-12-18 Protein Design Labs, Inc. Stable aqueous pharmaceutical formulations of daclizumab antibodies
NZ534492A (en) 2002-02-07 2009-10-30 Novozymes Delta Ltd Albumin-fused kunitz domain peptides
US20050222023A1 (en) 2002-02-07 2005-10-06 Hans-Peter Hauser Albumin-fused kunitz domain peptides
AU2003231865A1 (en) 2002-05-31 2003-12-19 Genzyme Corporation Alpha acyloxyacetamides for kallikrein and urokinase inhibition
DE60333758D1 (de) 2002-06-07 2010-09-23 Dyax Corp Prevention und Verringerung von Ischemia
US7153829B2 (en) 2002-06-07 2006-12-26 Dyax Corp. Kallikrein-inhibitor therapies
US7132100B2 (en) 2002-06-14 2006-11-07 Medimmune, Inc. Stabilized liquid anti-RSV antibody formulations
MXPA05000796A (es) 2002-07-24 2005-04-19 Hoffmann La Roche Aditivos de acidos polialquilenglicolicos.
AU2003257467B2 (en) 2002-07-24 2008-02-28 F. Hoffmann-La Roche Ag Pegylated T20 polypeptide
EP2386310B1 (en) 2002-08-28 2018-11-07 Dyax Corp. Methods for preserving organs and tissues
US8129330B2 (en) 2002-09-30 2012-03-06 Mountain View Pharmaceuticals, Inc. Polymer conjugates with decreased antigenicity, methods of preparation and uses thereof
US20040062748A1 (en) 2002-09-30 2004-04-01 Mountain View Pharmaceuticals, Inc. Polymer conjugates with decreased antigenicity, methods of preparation and uses thereof
US7314613B2 (en) 2002-11-18 2008-01-01 Maxygen, Inc. Interferon-alpha polypeptides and conjugates
GEP20084486B (en) 2002-12-26 2008-09-25 Mountain View Pharmaceuticals Polymer conjugates of interferon-beta with enhanced biological potency
PT1587907E (pt) 2003-01-07 2011-04-08 Dyax Corp Biblioteca de domínios de kunitz
CA2512680A1 (en) 2003-01-08 2004-07-29 Chiron Corporation Stabilized lyophilized compositions comprising tissue factor pathway inhibitor or tissue factor pathway inhibitor variants
US6989369B2 (en) 2003-02-07 2006-01-24 Dyax Corp. Kunitz domain peptides
EP1638579A2 (en) 2003-07-02 2006-03-29 Emory University Compositions and methods for use of a protease inhibitor and adenosine for preventing organ ischemia and reperfusion injury
EP1660537A2 (en) 2003-08-14 2006-05-31 Dyax Corp. Endotheliase-2 ligands
US20050089515A1 (en) 2003-08-29 2005-04-28 Dyax Corp. Poly-pegylated protease inhibitors
CA2537113A1 (en) 2003-08-29 2005-03-10 Dyax Corp. Modified protease inhibitors
WO2005023870A1 (ja) 2003-09-04 2005-03-17 Riken ＴＧＦ－β活性化制御領域の切断面を認識する抗体
WO2005027753A1 (en) 2003-09-19 2005-03-31 St. Jude Medical, Inc. Apparatus and methods for tissue gathering and securing
JP2007507538A (ja) 2003-10-02 2007-03-29 エラン ファーマシューティカルズ，インコーポレイテッド 疼痛軽減方法
US20060228331A1 (en) 2003-10-10 2006-10-12 Novo Nordisk A/S IL-21 Derivatives and variants
KR100570422B1 (ko) 2003-10-16 2006-04-11 한미약품 주식회사 대장균 분비서열을 이용하여 항체 단편을 분비·생산하는 발현벡터 및 이를 이용하여 항체 단편을 대량 생산하는 방법
WO2005041631A2 (en) 2003-10-21 2005-05-12 Dyax Corp. Endotheliase-1 ligands
EP1713929A2 (en) 2004-02-03 2006-10-25 Bayer HealthCare AG Diagnostics and therapeutics for diseases associated with plasma kallikrein (klkb1)
JP4775259B2 (ja) 2004-03-31 2011-09-21 味の素株式会社 アニリン誘導体
JP2008515774A (ja) 2004-08-03 2008-05-15 ダイアックス コーポレイション ｈＫ１結合タンパク質
US7235530B2 (en) 2004-09-27 2007-06-26 Dyax Corporation Kallikrein inhibitors and anti-thrombolytic agents and uses thereof
EP1835926A4 (en) 2004-11-22 2009-04-01 Dyax Corp PLASMINE-INHIBITING THERAPIES
US8841259B2 (en) 2005-02-24 2014-09-23 Joslin Diabetes Center Compositions and methods for treating vascular permeability
AU2006242998B2 (en) 2005-05-04 2012-03-22 Zealand Pharma A/S Glucagon-like-peptide-2 (GLP-2) analogues
US20070079096A1 (en) 2005-09-30 2007-04-05 Chih-Wei Chen Data storage unit access authorization table automatic rebuilding method and system
MXPA06011291A (es) 2005-09-30 2007-06-08 9141 0720 Quebec Inc Dispositivo de operacion de cierre motorizado con sistema de control electronico.
EP1981519B1 (en) 2005-12-29 2017-12-27 Dyax Corp. Protease inhibition
US7276480B1 (en) 2005-12-30 2007-10-02 Dyax Corp. Prevention and reduction of blood loss
EP2001500A4 (en) 2006-03-10 2010-07-28 Dyax Corp FORMULATIONS FOR ECALLANTIDE
SI2374472T1 (sl) 2006-03-16 2018-11-30 Dyax Corp., Sestavki in postopki za zdravljenje oftalmoloških motenj
CA2658523C (en) 2006-07-31 2012-06-12 Activesite Pharmaceuticals, Inc. Inhibitors of plasma kallikrein
WO2008060764A2 (en) 2006-10-05 2008-05-22 Drugtech Corporation Topical therapies for oral mucositis and other conditions
KR100846354B1 (ko) 2007-03-21 2008-07-15 (주) 프로탄바이오 혈청 당단백질부터 분리한 폐암 진단용 마커
WO2009026334A2 (en) 2007-08-21 2009-02-26 Genzyme Corporation Treatment with kallikrein inhibitors
CA2695012A1 (en) 2007-08-23 2009-02-26 Genzyme Corporation Treatment with kallikrein inhibitors
CA2715297A1 (en) 2008-02-13 2009-08-20 Dyax Corp. Improved methods for producing specific binding pairs
CN102264390A (zh) 2008-07-02 2011-11-30 新兴产品开发西雅图有限公司 Il6免疫治疗
WO2010048432A1 (en) 2008-10-22 2010-04-29 Dyax Corp. Combination treatments comprising protease binding proteins for inflammatory disorders
JP2013516389A (ja) 2009-01-06 2013-05-13 ダイアックス コーポレーション カリクレイン阻害剤による粘膜炎治療
CN101928346B (zh) 2009-07-31 2013-01-16 华中科技大学同济医学院附属同济医院 一种抗人组织激肽释放酶单克隆抗体及其制备
SI3459564T1 (sl) 2010-01-06 2022-06-30 Takeda Pharmaceutical Company Limited Proteini, ki vežejo plazemski kalikrein
ES2788100T3 (es) 2010-07-15 2020-10-20 Dow Agrosciences Llc Composiciones sólidas de herbicidas con coadyuvantes incorporados
JP2014506257A (ja) 2011-01-06 2014-03-13 ダイアックス コーポレーション 血漿カリクレイン結合タンパク質
WO2012142308A1 (en) 2011-04-13 2012-10-18 Activesite Pharmaceuticals, Inc. Prodrugs of inhibitors of plasma kallikrein
WO2012151247A2 (en) 2011-05-02 2012-11-08 Millennium Pharmaceuticals, Inc. FORMULATION FOR ANTI-α4β7 ANTIBODY
ES2732243T3 (es) 2012-02-16 2019-11-21 Santarus Inc Composiciones farmacéuticas de anticuerpos ANTI-VLA1 (CD49A)
US9216219B2 (en) 2012-06-12 2015-12-22 Novartis Ag Anti-BAFFR antibody formulation
JP6656926B2 (ja) * 2013-01-20 2020-03-04 ダイアックス コーポレーション ｐＫａｌ関連疾病の評価、アッセイおよび治療
EP3456744B1 (en) 2013-01-20 2023-03-29 Takeda Pharmaceutical Company Limited Evaluation and treatment of bradykinin-mediated disorders
CN111704672B (zh) 2013-03-15 2024-06-04 武田药品工业株式会社 抗血浆激肽释放酶抗体
KR20140119396A (ko) 2013-03-29 2014-10-10 삼성전자주식회사 단백질 약물의 액상 제형
AU2014340450B2 (en) 2013-10-21 2020-05-21 Takeda Pharmaceutical Company Limited Assays for determining plasma kallikrein system biomarkers
EA038532B1 (ru) 2014-01-21 2021-09-10 Такеда Фармасьютикал Компани Лимитед Способ лечения наследственного ангионевротического отека (hae)
IL295414B1 (en) 2014-03-27 2025-10-01 Takeda Pharmaceuticals Co Compositions and methods for treating macular edema due to diabetes
EP3286226A4 (en) 2015-03-30 2018-12-05 Dyax Corp. Plasma kallikrein inhibitors and uses thereof for preventing hereditary angioedema attack
US11286307B2 (en) 2015-12-11 2022-03-29 Takeda Pharmaceutical Company Limited Plasma kallikrein inhibitors and uses thereof for treating hereditary angioedema attack
BR112019005167A2 (pt) 2016-09-16 2019-07-02 Dyax Corp. método e kit para analisar uma amostra
MX2021002349A (es) 2018-08-30 2021-05-31 Takeda Pharmaceuticals Co Inhibidores de calicreína en plasmá y usos de los mismos para tratar ataque de angioedema hereditario.
EP3938404A1 (en) 2019-03-14 2022-01-19 Takeda Pharmaceutical Company Limited Plasma kallikrein inhibitors and uses thereof for treating hereditary angioedema attack
CN115297927A (zh) 2020-01-13 2022-11-04 武田药品工业株式会社 血浆激肽释放酶抑制剂及其用于治疗儿科遗传性血管性水肿发作的用途

Also Published As

Publication number Publication date
US10428158B2 (en) 2019-10-01
KR102555955B1 (ko) 2023-07-18
KR20230109785A (ko) 2023-07-20
AU2015235967A1 (en) 2016-10-06
US20150274841A1 (en) 2015-10-01
JP2017512790A (ja) 2017-05-25
AU2021200309A1 (en) 2021-03-18
US11046785B2 (en) 2021-06-29
JP7550251B2 (ja) 2024-09-12
BR112016022318A2 (pt) 2017-10-31
AU2024205262A1 (en) 2024-08-22
KR20160138220A (ko) 2016-12-02
EP3122782A1 (en) 2017-02-01
IL247942B (en) 2022-09-01
CN106459210A (zh) 2017-02-22
EP3122782A4 (en) 2017-09-13
IL247942A0 (en) 2016-11-30
US12084515B2 (en) 2024-09-10
JP6719384B2 (ja) 2020-07-15
JP7566716B2 (ja) 2024-10-15
WO2015148790A1 (en) 2015-10-01
AU2021200309B2 (en) 2024-05-02
IL295414B1 (en) 2025-10-01
JP2023029557A (ja) 2023-03-03
US20200115469A1 (en) 2020-04-16
US20220033521A1 (en) 2022-02-03
IL295414A (en) 2022-10-01
AU2015235967B2 (en) 2020-10-22
JP7003348B2 (ja) 2022-02-04
JP2020079246A (ja) 2020-05-28
JP2022023156A (ja) 2022-02-07

Similar Documents

Publication Publication Date Title
US12084515B2 (en) Compositions and methods for treatment of diabetic macular edema
US12110343B2 (en) Anti-plasma kallikrein antibodies
JP2017512790A5 (cg-RX-API-DMAC7.html)
BR112016022318B1 (pt) USO DE UM ANTICORPO QUE SE LIGA A UMA CALICREÍNA PLASMÁTICA ATIVA (PKal) E NÃO SE LIGA À PRECALICREÍNA HUMANA NO TRATAMENTO DE DOENÇAS DA RETINA
BR122024004106A2 (pt) Uso de um anticorpo que se liga a uma calicreína plasmática ativa (pkal) e não se liga à precalicreína humana no tratamento de doenças da retina
HK40021386A (en) Anti-plasma kallikrein antibodies

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20200323

EEER Examination request

Effective date: 20200323

EEER Examination request

Effective date: 20200323

EEER Examination request

Effective date: 20200323

EEER Examination request

Effective date: 20200323

EEER Examination request

Effective date: 20200323

EEER Examination request

Effective date: 20200323

EEER Examination request

Effective date: 20200323

EEER Examination request

Effective date: 20200323